SGT-001

N/A

Report date: 2023/10/26 16:20:20

Base Information

Drug NameSGT-001

Drug Alias NamerAAV9-CK8-h-µD5（Solid Biosciences）Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8（Solid Biosciences）SGT-001

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector

Mechanisms of ActionDystrophin gene transference

TargetsDystrophin

Therapy Area/IndicationsMuscular Dystrophy, Duchenne

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Missouri Solid Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesSolid Biosciences Inc

Inactive CompaniesN/A

Active IndicationsMuscular Dystrophy, Duchenne

Inactive IndicationsN/A

Other Information

ATC CodeN/A